PARP1 Olaparib Competitive Inhibitor Assay Kit
The PARP1 Olaparib Competitive Inhibitor Assay Kit is a competitive FP (fluorescent polarization) assay designed to measure the formation of a complex between PARP1 (poly(ADP-ribose) polymerase 1) and a fluorescent probe that contains the PARP1 inhibitor Olaparib. When the probe is bound to PARP1, FP is high. In the presence of a test compound able to bind to the same site in PARP1 as Olaparib, the Olaparib-containing fluorescent probe is displaced from PARP1 and remains in solution, resulting in low FP. The PARP1 Olaparib Competitive Inhibitor Assay Kit comes in a convenient 96-well format, with purified PARP1 enzyme, Olaparib-containing fluorescent-labeled probe, and assay buffer for 100 enzyme reactions.
Note: This kit is not appropriate for inhibitors expected to bind to PARP1 at different sites from Olaparib.
Figure 1: PARP1 Olaparib Competitive Inhibitor Assay Kit mechanism.
PARP1 binds to the Olaparib-containing fluorescent probe, forming a complex. This complex, when subjected to polarized excitation light, emits highly polarized light due to its restricted movement in solution. In the presence of a test compound (A), PARP1 may form a complex with either the test compound, if the compound has the same binding site of PARP1 as Olaparib, or with the Olaparib-containing fluorescent probe. If the test compound binds to PARP1 at the same site, the Olaparib-containing fluorescent probe remains in solution and rotates freely what is manifested by low FP. The decrease in FP value is proportional to the competitive binding of the test compound to PARP1.
This assay requires a fluorescent microplate reader capable of measuring fluorescence polarization (FP) to read the FP signal. For more information FP technology, visit our Tech Note: FP, assay principles and applications.
- Adjustable micropipettor and sterile tips
- Rotating or rocker platform
- Fluorescent microplate reader capable of measuring fluorescence polarization (λexc=485/20 nm and detection at λem=528/20 nm)
| Catalog # | Name | Amount | Storage |
| 80501 | PARP1, GST-Tag* | 5 µg | -80°C |
| 10 µM PARPi-FL | 5 µl | -80°C | |
| 5x PARPtrap™ Assay Buffer 2 | 2 x 1 ml | -80°C | |
| 79685 | 96-well black microplate | 1 | Room Temp |
* The initial concentration of enzyme is lot-specific and will be indicated on the tube containing the protein.
PARP1, also known as poly-(ADP-ribose) polymerase 1 or NAD+ ADP-ribosyltransferase 1, is part of the PARP family, and it is the most abundant member. ADP ribosylation, which is the addition of an ADP-ribose to a protein, is a reversible post-translational modification of proteins mostly involved in the DNA Damage Response (DDR) pathway. Poly-ADP-ribosylation (termed PARylation) is the addition of linear or branched chains of ADP-ribose. PARP1 participates in DNA repair by non-homologous end joining (NHEJ), homologous recombination (HR), microhomology-mediated end-joining (MMEJ) and nucleotide excision repair. Dysfunction of DDR pathways can lead to oncogenesis. Overexpression of PARP1 has been found in breast and colon cancer, neuroblastoma, and others. This overexpression can lead to increasing MMEJ, an error-prone DNA repair mechanism, and genome instability leading to cancer. In addition to being involved in DDR, PARP1 is also linked to inflammation and type I diabetes. PARP1 inhibitors have been used in cancer treatment with success. In addition to reducing MMEJ, the use of PARP1 inhibitors can lead to synthetic lethality when homologous recombination repair (HRR) mechanisms are already defective, as in the case of BRCA1 (breast cancer susceptibility protein type 1) and BRCA2 deficient cells. Further understanding of the molecular pathways involving PARP1, and this contribution to disease, will continue to pave the way for new therapies for PARP1-linked diseases.
Marques M., et al., 2019 Oncogene 38 (12): 2177-2191.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.